Drugs / 2HPβCD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06489340 | Jun 2025 → Aug 2026 | diabetic kidney disease | ZyVersa Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-10-30 | ZyVersa Therapeutics, Inc. | Regulatory Variant Pharmaceuticals Submits Application for U.S. Orphan Drug Designation for VAR 200 (2-Hydroxypropyl-β-Cyclodextrin) To Treat Focal Segmental Glomerulosclerosis (FSGS) stockpr.com ↗ |
| 2018-10-24 | ZyVersa Therapeutics, Inc. | Results Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-β-Cyclodextrin (2HPβCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS) stockpr.com ↗
Variant Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, announced today publication of preclinical data evaluating 2HPβCD in experimental models of Alport Syndrome and FSGS. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2HPβCD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06489340 ↗ |
| Route | Intravenous | “given intravenously” NCT06489340 ↗ |